Beta-thalassemia cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
Overview
The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as access to healthcare resources, availability of blood products, affordability of chelation therapy, and overall disease management.
Cost-effectiveness of therapy
Cost-effectiveness of therapy
The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as[1]:
- Access to healthcare resources
- Availability of blood products
- Affordability of chelation therapy
- Overall disease management
References
References
- ↑ Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, Blanche S, Benaouadi S, Brice T, Tuchmann-Durand C, Ribeil JA, Magrin E, Lissillour E, Rochaix L, Cavazzana M, Durand-Zaleski I (June 2019). “Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation”. Hum Gene Ther. 30 (6): 753–761. doi:10.1089/hum.2018.178. PMID 30700149.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH